Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

Immunovaccine raises C$10M in bought deal

June 1, 2017 8:59 PM UTC

On May 31, immunotherapy company Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF) raised C$10 million ($7.4 million) through the sale of 7.7 million shares at C$1.30 in a bought deal underwritten by Echelon ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Imv Inc.